Casey Cunningham, MD
Chief Medical Officer
Dr. Cunningham received his fellowship training in oncology and hematology at the Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women’s Hospital in Boston, where he established a basic research laboratory in Cell and Molecular Biology.
Casey received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. Casey returned to Texas in 1999 as the Associate Director of the Mary Crowley Cancer Research Center in Dallas. The MCCRC performs early phase drug development and Casey was the principal investigator on numerous trials, with a particular emphasis on gene and cell-based therapies. He left this position in 2007 to found a biotechnology company and shortly thereafter also joined Sante Ventures as Chiel Scientific Officer. In addition to performing scientific and technical assessments for the fund, Casey has served in operating roles as Chief Medical Officer of three different portfolio companies, Terapio, Molecular Templates and currently, Iterion Pharmaceuticals (formerly Beta Cat Pharmaceuticals).